



CREATHOR
VENTURE



Pressrelease

2011/06/27

Creathor Venture accelerates growth of SIRION BIOTECH with further investment

Bad Homburg, Germany – Creathor Venture and current investors invest in SIRION BIOTECH and provide further funding.

In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION's core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.

A part of the new proceeds will be used to further promote already developed technologies and services. One focus will be an internationalization strategy to generate further clients in the EU and the US-market, where SIRION already has first prominent clients such as the FDA. In addition the funds will be used to further support the development of new vector-technologies that are essential for the vaccine-industry. First patents were filed in 2010 and cover a technology that will be essential for developing new vaccines against human Cytomegalo-Virus, Human Immundeficiency-Virus or Tuberculosis.

Karlheinz Schmelig, Partner at Creathor Venture states, that the current market situation and the recent results of the internal research activities were the reasons for the investemnt: "SIRION was able to prove both a significant market need and demand for its products and showed that it is able to develop innovative products."

This statement is complemented by the management-team, Drs. Jürgen Flach (CEO) and Christian Thirion (CSO): „Due to the current round we will be able to raise the significant sales potential of our pipeline projects and launch new technologies in new markets such as the vaccine-market.

About Creathor Venture

Creathor Venture invests in technology-oriented companies and entrepreneurs from the fields of life science, IT, telecommunication, new media, new materials, electronics, nanotechnology and clean tech. With 25 years of experience in the venture capital market, acting as lead investor for more than 200 companies and participating in over 20 IPOs we provide not only capital but also industry knowledge, expertise at building companies, and the network to develop a sustainable business model with a globally competitive advantage. The management team at Creathor Venture includes the founder of former Technologieholding, Dr. Gert Köhler as well as Ingo Franz and Karlheinz Schmelig. Examples of successful companies the partners have managed from the first round of financing to IPO are Micronas (SMI), SEZ (SMI), Intershop (Prime Segment), Infovista (NASDAQ, Nouveau Marché), POET (Prime Segment, NASDAQ), Wavelight (Prime Segment), Epigenomics (Prime Segment) and ITN Nanovation (Prime Segment). www.creathor.de

Contact:

Ute Molders
CREATHOR VENTURE Management GmbH
Marienbader Platz 1
61348 Bad Homburg
Tel: +49 6172 13 07 20
Email: ute.molders@creathor.de

About SIRION BIOTECH

SIRION BIOTECH GmbH is a biotech company that produces genetically modified cells and is a technology provider in the area of viral vector systems. The company founded in 2005 is located in the Innovations- und Gründerzentrum Biotechnologie IZB in Martinsried near Munich. The expert in RNAi technology offers lead-through service projects in target validation, screening and drug discovery using front running techniques and assay systems. With its strong expertise in mammalian cell culture and viral vector technology SIRION BIOTECH serves as a contract research partner for preclinical R&D, and licenses vector technology for vaccine development. The academic team has more than 20 years of experience in mammalian cell culture and viral vector technology. Close cooperation with leading research institutes puts SIRION BIOTECH at the forefront for development of cell systems for pharmaceutical research. SIRION BIOTECH currently operates projects for major pharmaceutical and biotech companies in Europe and USA and has ongoing collaborations with leading academic and governmental research institutes. www.sirion-biotech.de

Contact:

Dr. Christian Thirion
SIRION BIOTECH GmbH
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel: +49 89 70096199
Email: Thirion@sirion-biotech.de

About High-Tech Gründerfonds

High-Tech Gründerfonds invests venture capital in promising technology companies that turn innovative concepts into viable businesses. Seed financing aims to help start-ups guide their innovation to the prototype or proof-of-concept stage or to market launch. High-Tech Gründerfonds provides seed financing of approximately €500,000. It supports high-tech companies by way of its investment managers and its highly-qualified network of coaches, investors and specialists. In individual cases it can invest up to a total of €2 m per company. The investors in this public private partnership are the German Federal Ministry for Business and Technology, the KfW Banking Group as well as the six industrial groups of BASF, Deutsche Telekom, Siemens, Robert Bosch, Daimler and Carl Zeiss. High-Tech Gründerfonds has an investment volume totalling approx. €272 m.

Contact:

High-Tech Gründerfonds Management GmbH
Marco Winzer
Tel: 0228/823001-00
Email: info@hight-tech-gruenderfonds.de Homepage: www.high-tech-gruenderfonds.de

About Bayern Kapital and its Seed- und Clusterfonds:

Bayern Kapital was initiated in 1995 by the Bavarian Government within the program "Offensive Zukunft Bayern" [Future Bavaria], to support young innovative Bavarian companies with equity funding. So far Bayern Kapital has invested approx. € 168 m in more than 200 innovative high-tech companies. As a regional partner Bayern Kapital offers its support and is currently managing a total volume of around €214 m.

Contact:

Monika Steger
Bayern Kapital GmbH
Ländgasse 135 a
84028 Landshut
Tel: +49 871 923250
info@bayernkapital.de

About KfW banking group – ERP-Startfonds –

KfW finances and supports, among other things, business start-ups, small and medium-sized enterprises (SME) as well as investments in economic growth and employment projects in Germany.

The ERP Start-up-Fund, administered and co-financed by KfW, offers equity financing for innovative, technology-based enterprises with excellent growth prospects. The fund finances research and product development as well as the launching of new products, procedures and services. KfW always cooperates with a lead investor and exclusively adopts market conditions.

Contact:

KfW Bankengruppe - Branch Bonn

Stefan Frings

Ludwig-Erhard-Platz 1-3

53179 Bonn

Germany

Tel.: +49 228 8310

Fax: +49 228 8317255

stefan.frings@kfw.de

<http://www.kfw.de/>